Clinical trial
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
NCT00007904 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00007904 |
|---|---|
| Title | Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes |
| Official title | A Phase II Study Of Safety And Tolerability Of Adjuvant Chemotherapy With Continuous Infusion Paclitaxel And Dose Intense Cyclophosphamide And Hematopoietic Growth Factor Support Followed By Doxorubicin For Stage II-IIIA Breast Cancer Involving Greater Than or Equal to 10 Lymph Nodes |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | filgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, adjuvant therapy, radiation therapy |
| Enrollment | 16 |
| Start date | Jul 1, 2000 |
| Primary completion | Jun 1, 2006 |
| Completion | Sep 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: